RVXCF (Resverlogix) Beginning Cash Position : $0.06 Mil (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Resverlogix Beginning Cash Position?

Resverlogix's Beginning Cash Position for the quarter that ended in Sep. 2024 was $0.06 Mil.

Resverlogix's quarterly Beginning Cash Position increased from Mar. 2024 ($0.01 Mil) to Jun. 2024 ($0.06 Mil) and increased from Jun. 2024 ($0.06 Mil) to Sep. 2024 ($0.06 Mil).

Resverlogix's annual Beginning Cash Position declined from Dec. 2021 ($0.09 Mil) to Dec. 2022 ($0.01 Mil) but then increased from Dec. 2022 ($0.01 Mil) to Dec. 2023 ($0.04 Mil).

Resverlogix Beginning Cash Position Historical Data

The historical data trend for Resverlogix's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Beginning Cash Position Chart

Resverlogix Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

0.12

7.69

0.09

0.01

0.04

Resverlogix Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Beginning Cash Position	Get a 7-Day Free Trial															0.08	0.10	0.01	0.06	0.06

Resverlogix Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Resverlogix Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Resverlogix's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Resverlogix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (OTCPK:RVXCF) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

0VF9:UK RFS:Germany RVX:Canada

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.